OncoMatch/Clinical Trials/NCT07023484

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Is NCT07023484 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Carboplatin plus Paclitaxel for ovarian cancer.

Phase 2RecruitingThe University of Hong KongNCT07023484Data as of May 2026

Treatment: Carboplatin plus Paclitaxel — About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients and compare this with the standard clinical practice.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Biomarker criteria

Required: BRCA1 any tested

Required: BRCA2 any tested

Disease stage

Required: Stage III, IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

adequate hematologic function for chemotherapy

Kidney function

adequate renal function for chemotherapy

Liver function

adequate liver function for chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify